Abstract
Get full access to this article
View all access options for this article.
References
1.Biotechnology Industry Organization . 2011 . Companion diagnostics: BIO comments on FDA draft guidance . http://www.bio.org/advocacy/letters/companion-diagnostics-bio-comments-fda-draft-guidance.
July
31
2012 .
2.
La Thangue
NB
,
Kerr
DJ
2011 . Predictive biomarkers: a paradigm shift towards personalized medicine . Nat Rev Clin Oncol , 8 :587 -596 .
3.
Pollack
A
. 2011 . A push to tie new drugs to testing. New York Times . http://www.nytimes.com/2011/12/27/health/pressure-to-link-drugs-and-companion-diagnostics.html.
July
31
2012 .
4.
Rajan
A
,
Jacobson
M
,
Xie
K
2011 . Developing and commercializing companion diagnostics . European Medical Device Technology . http://www.emdt.co.uk/article/developing-and-commercialising-companion-diagnostics.
August
14
2012 .
5.
Thomas
J
,
Stratton
E
,
Keppens
M
2012 . Companion diagnostics: emerging strategies and issues in pharmaceutical development . Expert Rev Mol Diagn , 12 :561 -563 .
6.U.S. Food and Drug Administration . 2011 . FDA News Release: FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer . http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm.
July
31
2012 .